Supernus Pharmaceuticals
SUPN
273 hedge funds and large institutions have $1.86B invested in Supernus Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 85 increasing their positions, 94 reducing their positions, and 19 closing their positions.
177% more call options, than puts
Call options by funds: $982K | Put options by funds: $355K
153% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 19
20% more capital invested
Capital invested by funds: $1.56B → $1.86B (+$305M)
12% more funds holding
Funds holding: 244 → 273 (+29)
2.44% more ownership
Funds ownership: 106.23% → 108.67% (+2.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 94
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
+$17M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$12.6M |
| 3 |
Goldman Sachs
New York
|
+$9.65M |
| 4 |
HSBC Holdings
London,
United Kingdom
|
+$7.38M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$5.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$10.2M |
| 2 |
AC
Armistice Capital
New York
|
-$5.49M |
| 3 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
-$5.24M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.65M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$3.41M |
SUPN Hedge Fund Activity: Q3 2024 in Review
273 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q3 2024, worth a combined $1.86B — up 20% from $1.56B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new SUPN positions and 19 closed out — a net gain of 29 holders — while 85 added to existing stakes and 94 trimmed.
The largest buyer was American Century Companies, adding an estimated $17M. The largest seller was BlackRock, cutting an estimated $10.2M.
- 273 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q3 2024, up from 244 in Q2 2024.
- Funds reported $1.86B of Supernus Pharmaceuticals stock for Q3 2024, up 20% quarter-over-quarter.
- 48 funds opened new Supernus Pharmaceuticals positions in Q3 2024 and 19 closed out, a net change of +29 holders.
- The largest Supernus Pharmaceuticals buyer in Q3 2024 was American Century Companies, an estimated $17M added.
- The largest Supernus Pharmaceuticals seller in Q3 2024 was BlackRock, an estimated $10.2M sold.
Based on aggregated 13F filings for Q3 2024.